Showing results (311-320 of 2,767) with videos related to
Sort By:
Pageof 277
Archives of Dermatology|November 16, 2001
Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 casesP Wolkenstein, J Zeller, J Revuz, et al.Dermatology (Basel, Switzerland)|January 1, 1997
Schwannomatosis: a clinical entity distinct from neurofibromatosis type 2P Wolkenstein, H Benchikhi, J Zeller, et al.Plos One|April 4, 2015
Keep calm and carry on: improved frustration tolerance and processing speed by transcranial direct current stimulation (tDCS)Christian Plewnia, Philipp A Schroeder, Roland Kunze, et al.Archives of Dermatology|February 18, 2003
Clinical risk factors for mortality in patients with neurofibromatosis 1: a cohort study of 378 patientsKiarash Khosrotehrani, Sylvie Bastuji-Garin, Jacques Zeller, et al.Cambridge Quarterly of Healthcare Ethics : CQ : the International Journal of Healthcare Ethics Committees|September 11, 2018
Do New Neuroimaging Findings Challenge the Ethical Basis of Advance Directives in Disorders of Consciousness?Orsolya Friedrich, Andreas Wolkenstein, Ralf J Jox, et al.Annales De Dermatologie Et De Venereologie|January 1, 1995
[Eruptive nevus in the course of Lyell syndrome]D Jullien, G Prévot, P Wolkenstein, et al.Journal of Clinical Pathology|June 1, 1996
Caseous necrosis in cutaneous leishmaniasisE Peltier, P Wolkenstein, M Deniau, et al.Dermatology (Basel, Switzerland)|November 23, 2007
Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trialsLaurence Le Cleach, Olivier Chassany, Annabelle Levy, et al.Plos One|October 18, 2019
Quantitation of eumelanin and pheomelanin markers in diverse biological samples by HPLC-UV-MS following solid-phase extractionSusanne Affenzeller, Holm Frauendorf, Tobias Licha, et al.Arzneimittel-Forschung|March 1, 1996
Effects of two protein-free peptide derivatives on passive avoidance behaviour of 24-month-old ratsB Hutter-Paier, U Eggenreich, M WindischPageof 277